The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.
An article from
Emerging biotech
The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.
Published June 24, 2026
A micrograph image of influenza A virus.
UK biotech secures $115M to advance portfolio of virus-targeting antibodies
Exclusive: RA Capital backs intranasal viral prophylactic with $34M and a plan for Phase 2b
A New $500 Million Fund Is Trying to Eliminate the Common Cold
AbbVie's Big Immunology Acquisition
Proliant Health & Biologicals Raises the Albumin Standard with AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin
RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.
NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from…
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi…
Antogen Secures Seed Financing to Advance Next-Generation Immune Surveillance Diagnostics
